Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
September 06, 2023 08:00 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics Announces Participation in Upcoming Conferences in September
September 05, 2023 08:00 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 14, 2023 16:05 ET
|
Lisata Therapeutics, Inc.
Cash runway projected into first quarter 2026 based on capital conservation measures implemented without impact to clinical development pipeline Technology transfer agreement executed for Company’s...
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma
August 08, 2023 08:00 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time
August 07, 2023 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors
July 11, 2023 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference
June 12, 2023 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1
May 24, 2023 08:00 ET
|
Lisata Therapeutics, Inc.
Target enrollment increased to 155 subjects with the addition of a cohort testing a second dose of LSTA1 Results to be used to explore possible conditional approvals globally Futility analysis...
Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 09, 2023 16:05 ET
|
Lisata Therapeutics, Inc.
Conference call scheduled for today at 4:30 p.m. Eastern time BASKING RIDGE, N. J., May 09, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a...
Lisata Therapeutics to Host First Quarter 2023 Financial Results Conference Call on Tuesday, May 9th, at 4:30 p.m. Eastern Time
May 02, 2023 09:07 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...